ANIP
Price
$97.46
Change
+$2.10 (+2.20%)
Updated
Sep 18, 04:59 PM (EDT)
Capitalization
2.12B
48 days until earnings call
HROW
Price
$45.39
Change
+$2.24 (+5.19%)
Updated
Sep 18, 04:59 PM (EDT)
Capitalization
1.59B
60 days until earnings call
Interact to see
Advertisement

ANIP vs HROW

Header iconANIP vs HROW Comparison
Open Charts ANIP vs HROWBanner chart's image
ANI Pharmaceuticals
Price$97.46
Change+$2.10 (+2.20%)
Volume$5.3K
Capitalization2.12B
Harrow
Price$45.39
Change+$2.24 (+5.19%)
Volume$6.49K
Capitalization1.59B
ANIP vs HROW Comparison Chart in %
Loading...
ANIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANIP vs. HROW commentary
Sep 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIP is a Hold and HROW is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 19, 2025
Stock price -- (ANIP: $95.33 vs. HROW: $43.10)
Brand notoriety: ANIP and HROW are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ANIP: 81% vs. HROW: 105%
Market capitalization -- ANIP: $2.12B vs. HROW: $1.59B
ANIP [@Pharmaceuticals: Generic] is valued at $2.12B. HROW’s [@Pharmaceuticals: Generic] market capitalization is $1.59B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.35B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIP’s FA Score shows that 1 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • ANIP’s FA Score: 1 green, 4 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than ANIP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIP’s TA Score shows that 2 TA indicator(s) are bullish while HROW’s TA Score has 5 bullish TA indicator(s).

  • ANIP’s TA Score: 2 bullish, 5 bearish.
  • HROW’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, HROW is a better buy in the short-term than ANIP.

Price Growth

ANIP (@Pharmaceuticals: Generic) experienced а -2.19% price change this week, while HROW (@Pharmaceuticals: Generic) price change was +10.88% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +26.50%. For the same industry, the average monthly price growth was +26.53%, and the average quarterly price growth was +60.52%.

Reported Earning Dates

ANIP is expected to report earnings on Nov 05, 2025.

HROW is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+26.50% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANIP($2.12B) has a higher market cap than HROW($1.59B). ANIP YTD gains are higher at: 72.449 vs. HROW (28.465). ANIP has higher annual earnings (EBITDA): 89M vs. HROW (32.1M). ANIP has more cash in the bank: 224M vs. HROW (53M). HROW has less debt than ANIP: HROW (231M) vs ANIP (622M). ANIP has higher revenues than HROW: ANIP (747M) vs HROW (228M).
ANIPHROWANIP / HROW
Capitalization2.12B1.59B133%
EBITDA89M32.1M277%
Gain YTD72.44928.465255%
P/E Ratio51.82N/A-
Revenue747M228M328%
Total Cash224M53M423%
Total Debt622M231M269%
FUNDAMENTALS RATINGS
ANIP vs HROW: Fundamental Ratings
ANIP
HROW
OUTLOOK RATING
1..100
8216
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
2444
SMR RATING
1..100
9396
PRICE GROWTH RATING
1..100
3841
P/E GROWTH RATING
1..100
9310
SEASONALITY SCORE
1..100
n/a48

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HROW's Valuation (84) in the Pharmaceuticals Other industry is in the same range as ANIP (94). This means that HROW’s stock grew similarly to ANIP’s over the last 12 months.

ANIP's Profit vs Risk Rating (24) in the Pharmaceuticals Other industry is in the same range as HROW (44). This means that ANIP’s stock grew similarly to HROW’s over the last 12 months.

ANIP's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as HROW (96). This means that ANIP’s stock grew similarly to HROW’s over the last 12 months.

ANIP's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as HROW (41). This means that ANIP’s stock grew similarly to HROW’s over the last 12 months.

HROW's P/E Growth Rating (10) in the Pharmaceuticals Other industry is significantly better than the same rating for ANIP (93). This means that HROW’s stock grew significantly faster than ANIP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIPHROW
RSI
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 15 days ago
74%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ANIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAGIX10.80N/A
N/A
Fidelity Capital & Income
GCPYX21.31N/A
N/A
Gateway Equity Call Premium Y
TQSIX24.85N/A
N/A
T. Rowe Price Integrated US SMCC Eq I
GOFFX52.11N/A
N/A
Invesco Global Opportunities R5
STSVX19.78-0.01
-0.05%
BNY Mellon Sm Cp Val I

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with OGI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then OGI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
+0.50%
OGI - HROW
34%
Loosely correlated
+0.57%
TKNO - HROW
33%
Poorly correlated
-2.43%
AMRX - HROW
31%
Poorly correlated
-1.33%
ELAN - HROW
31%
Poorly correlated
-1.07%
ANIP - HROW
29%
Poorly correlated
-2.28%
More